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Abstract
Background: The family of proprotein convertases has been recently implicated in tumorigenesis
and metastasis in animal models. However, these studies have not yet been completely
corroborated in human tumors.
Methods: Using RT PCR, immunoblot and immunohistochemistry we assessed the presence and
the processing patterns of the convertases PC1 and PC2 as well as the PC2 specific chaperone 7B2
in human liver metastases originating from colorectal cancer and compared them to unaffected and
normal liver. Furthermore, we assessed the presence and processing profiles of PC1, PC2 and 7B2
in primary colon cancers.
Results: mRNA, protein expression, and protein cleavage profiles of proprotein convertases 1 and
2 are altered in liver colorectal metastasis, compared to unaffected and normal liver. Active PC1
protein is overexpressed in tumor, correlating with its mRNA profile. Moreover, the enhanced
PC2 processing pattern in tumor correlates with the overexpression of its specific binding protein
7B2. These results were corroborated by immunohistochemistry. The specific and uniform
convertase pattern observed in the metastases was present only in a fraction of primary colon
cancers.
Conclusion: The uniformly altered proprotein convertase profile in liver metastases is observed
only in a fraction of primary colon cancers, suggesting possible selection processes involving PCs
during metastasis as well as an active role of PCs in liver metastasis. In addition, the exclusive
presence of 7B2 in metastatic tumors may represent a new target for early diagnosis, prognosis
and/or treatment.
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Liver metastasis remains the major cause of therapeutic
failure in colorectal carcinoma. Amongst the 300,000
people that are given the diagnosis of colorectal cancer
(CRC) every year in Europe and North America, 60% will
eventually develop liver metastases, and several of them
will succumb from their disease. Metastasis microenviron-
ment conditioned by the tumor itself, may represent an
alternative to the "seed-soil" theory. Indeed recent reports
have demonstrated the pivotal role of the proprotein con-
vertases (PCs) (1) in tumor growth and metastasis of HT-
29 human colon carcinoma cells (2), lung (3) or breast
cancer cells (4). To date eight members of this family have
been identified, namely furin, PC1/PC3, PC2, PC4,
PACE4, PC5/PC6, PC7/LPC/PC8 and SKI-1/S1P [1-7].
Amongst the PCs, PC1 and PC2 are unique due to their
processing activity specific to the regulated secretory path-
way, and their localization in dense core secretory gran-
ules. Both proteins are synthesized in the Endoplasmic
Reticulum (ER) as zymogens (primary cleavage of the
zymogen of proPC1 occurs in the ER while that of proPC2
occurs in the granules), transported through the Golgi
apparatus, and the Trans Golgi Network (TGN) into
mature secretory granules, and both are proteolytically
activated along the way. The proper trafficking and
processing of proPC2 into its active form is dependent on
7B2, a chaperone-like protein [8]. This bifunctional
polypeptide has been shown to promote proPC2 cleavage
to the active PC2 form with its N-terminal domain, but
also to inhibit further PC2 processing with its C-terminal
domain. The exact biological significance of this protein
has not been elucidated yet, although its deletion in mice
leads to a Cushing's-like syndrome [9]. Finally, recently a
specific PC1 inhibitor, ProSAAS has been identified [10],
but its physiological function remains unclear.
The purpose of this study is to examine the expression and
processing patterns of PC1 and PC2 in human CRC liver
metastases and to compare these profiles with those
observed in unaffected and normal liver. Furthermore, we
assessed the processing patterns of these convertases in
primary colon cancers. Finally, we attempt to shed light
into the PC1 and PC2 processing mechanisms and their
potential impact on CRC liver metastasis.
Methods
Human liver specimens
Tumor specimens and their unaffected counterparts (Fig.
7D) were collected from 14 patients (proper informed
consent obtained) that underwent liver resection for CRC
metastases. Normal liver specimens were obtained from
organ donors. All the specimens were harvested immedi-
ately after resection and were snap frozen in liquid nitro-
gen.
Human colon cancer specimens
In a similar fashion, colon cancer specimens with unaf-
fected colon were collected from 5 patients (proper
informed consent obtained) that underwent colon resec-
tion for primary colon cancer (pathology proven adeno-
carcinoma). The specimens were harvested immediately
after resection and were snap frozen in liquid nitrogen.
PCR primers
PC1 primers were designed as follows f5'-TGGCTT-
GCTAAATGCCAAAGCTC-3'/r5'-ATCCACCATCTTCTC-
CACCCC-3' (annealing temperature 60°C), PC2 primers
were f5'-GTCCTTGATGCAGGTGCCATC-3'/r5'-ACTCCT-
TCAGCACCCCCTTC-3' (annealing temperature 62°C)
and 7B2 primers were f5'-CAC CAG GCC ATG AAT CTT-
3'/r5'-CTG GAT CCT TAT CCT CAT CTG-3' (annealing
temperature 61°C. GAPDH was used as standard and for
normalization (f5'-CCC TTC ATT GAC CTC AAC TAC
ATG GT-3'/r5'-GAG GGG CCA TCC ACA GTC TTC TG-3')
(annealing temperature 58°C).
Antibodies
Rabbit antisera raised either against PC1 (amino acids
621–726, Figure 1B), PC2 (amino acids 529–637, Figure
2B) or 7B2 (amino acids 32–39, Figure 3B) were used.
RNAs and proteins extraction
RNA was extracted using Trizol (Invitrogen) according to
the manufacturer's instructions. Semi-quantitative RT-
PCR analysis was performed as previously described [11].
For protein extraction, approximately 0.5 mg of sample
tissues were homogenized as previously described [12].
TX-100 was added to a 1% final concentration and tissue
extract solubilized for 30' at 4°C. Lysates were then centri-
fuged at 10000 g for 2 × 30' at 4°C. Protein concentrations
in the supernatants were determined using the Bradford
method. For every immunoblot analysis 100 µg of protein
were used.
Immunohistochemistry
4 µm-thick, formalin-fixed, paraffin-embedded tissue sec-
tions, were treated as previously described [13]. The slides
were incubated with anti-PC1, PC2 and 7B2 antibodies at
a 1:2000 dilution, revealed with biotinylated goat-anti-
rabbit IgG-B (1:200), combined with Histocain-plus kit,
followed by 3-amino-9-ethylcarbazole (AEC) chromogen
and counterstaining with hematoxylin.
Statistical analysis
Data are expressed as means ± SD. Comparisons between
the specimens were performed using student's t-test. A
value of p < 0.005 was considered statistically significant.Page 2 of 11
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Expression of PC1 in normal and unaffected liver compared to colorectal (CRC) liver metastasesFigure 1
Expression of PC1 in normal and unaffected liver compared to colorectal (CRC) liver metastases. A. Quantifica-
tion of PC1 mRNA expression respectively, in 3 normal (N), 14 tumor (T) and 14 unaffected (U) liver samples. Quantification 
was obtained by the ratio of the optical density of PC1 PCR amplification products over GAPDH. Standard error of mean 
(SEM) is indicated. Asterisk indicates a statistically significant difference (P < 0.04). B. Schematic representation of PC1 struc-
ture. The antigenic region against which the antibody was raised is mentioned (YAb). Cleavage sites are indicated (arrows). C. 
PC1 cleavage profile in normal (N1-N3, top panel), unaffected (U1-U2) and tumor (T1-T2, bottom panel) samples. Normal 
liver samples (N1-N3) derived from three different organ donors. T1/U1 and T2/U2 came from two independent patients. PC1 
immunoblotting was done on a total of 3 normal, 14 metastasis and 14 unaffected liver samples, and was repeated three times. 
D. Relative amounts of total PC1 (C, left panel) protein, in tumor (T), unaffected (U) and normal liver (N), expressed as a ratio 
over normal liver samples. Ratios of p84/p66 PC1 isoforms (C, right panel) in the same samples are calculated. SEM is indicated. 
Simple and double asterisks indicate statistically significant differences (P < 0.05).
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Expression of PC2 in normal and unaffected liver compared to colorectal (CRC) liver metastasesFigure 2
Expression of PC2 in normal and unaffected liver compared to colorectal (CRC) liver metastases. A. Quantifica-
tion of PC2 mRNA expression respectively, in 3 normal (N), 14 tumor (T) and 14 unaffected (U) liver samples. Quantification 
was obtained by the ratio of the optical density of PC2 PCR amplification products over GAPDH. Standard error of mean 
(SEM) is indicated. Asterisk indicates a statistically significant difference (P < 0.003). B. Schematic representation of PC2 struc-
ture. The antigenic region against which the antibody was raised is mentioned (YAb). Cleavage sites are indicated (arrows). C. 
PC2 cleavage profile in normal (N1-N3, top panel), unaffected (U1-U2) and tumor (T1-T2, bottom panel) samples. Normal 
liver samples (N1-N3) derived from three different organ donors. T1/U1 and T2/U2 came from two independent patients. PC1 
immunoblotting was done on a total of 3 normal, 14 metastasis and 14 unaffected liver samples, and was repeated three times. 
D. Relative amounts of total PC2 (C, left panel) protein, in tumor (T), unaffected (U) and normal liver (N), expressed as a ratio 
over normal liver samples. Ratios of p75/p66 PC2 isoforms (C, right panel) in the same samples are calculated. SEM is indicated. 
Simple and double asterisks indicate statistically significant differences (P < 0.05).
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Expression of 7B2 in normal and unaffected liver compared to colorectal (CRC) liver metastases. A. Quantifica-
tion of 7B2 mRNA expression respectively, in 3 normal (N), 14 tumor (T) and 14 unaffected (U) liver samples. Quantification 
was obtained by the ratio of the optical density of 7B2 PCR amplification products over GAPDH. Standard error of mean 
(SEM) is indicated. Asterisk indicates a statistically significant difference (P < 0.003). B. Schematic representation of 7B2 struc-
ture. The furin cleavage site is shown (arrow). The antigenic region against which the antibody was raised is indicated (YAb). C. 
7B2 immunoblots in normal liver (N1-N3, top panel), in tumor (T1, T2, bottom panel) and unaffected (U1, U2, bottom panel) 
liver, indicating presence of 7B2 protein only in tumor. Corresponding gels stained with Coomassie blue G250 (CS) are shown. 
Experiments were repeated three times.
Results
PC1 and PC2 mRNA are expressed in both normal and 
unaffected liver but their expression is differentially 
regulated in tumor
We initially assessed the presence of the mRNA encoding
PC1 and PC2 in liver CRC metastatic tumors versus unaf-
fected and normal livers. PC1 and PC2 RT-PCR amplifica-
tion products were of the expected size, 553 bp and 422
bp respectively. PC1 mRNA expression was two-fold
higher in areas of tumor compared to areas of unaffected
and normal liver (P < 0.04, Figure 1A). In contrast, PC2
mRNA was overexpressed two-fold in areas of unaffected
and normal liver compared to areas of metastasis (P <
0.003, Figure 2A).
PC1 and PC2 protein expression and maturation are 
altered in tumor
To correlate mRNA and protein expression, we examined
total sample lysates by immunoblotting. Relative
amounts of protein were quantified by scanning densit-
ometry of the immunoblots. Interestingly, the anti-PC1
antibody (Fig. 1B) revealed two immunoreactive species
of 84 and 66 kDa, respectively (Fig. 1C), in tumor (T),
unaffected (U), and normal (N) liver. The higher molecu-
lar mass isoform (84 kDa) corresponded to the full-length
active PC1 whereas the C-terminally immunoreactive 66
kDa isoform was likely to be an N-terminally truncated,
inactive form of PC1 (Fig. 1B) (14,15). In tumors the total
amount of PC1 (p84+p66) was ~2.5-fold more elevatedPage 5 of 11
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panel). Moreover the ratio of the 84 kDa active form over
the 66 kDa form was also ~2.5 times higher than in both
unaffected and normal liver (Fig. 1D, right panel). Immu-
noblot analysis with anti-PC2 antibody (Fig. 2B) revealed
two species of 75 and 66 kDa respectively, representing
the inactive proPC2 isoform and the cleaved, active PC2
(Fig. 2C) [14]. In contrast to PC1, the amount of total PC2
(p75+p66) was higher in unaffected and normal liver
than in metastasis (Fig. 2D, left panel). Nevertheless a
similar pattern of processing was observed, i.e. in metasta-
sis the fully active 66 kDa form predominates over the
inactive 75 kDa pro-form, while in unaffected and normal
liver the proPC2 isoform was more abundant. Again the
PC2 processing ratio of active PC2 (p66) over the inactive
proPC2 (p75) in tumor versus unaffected and normal
liver indicated a ~10-fold increase in PC2 maturation in
liver metastasis (Fig. 2D, right panel). In conclusion, alter-
ation of PC1 and PC2 processing, lead to increased accu-
mulation of active isoforms of both convertases in liver
metastasis.
The PC2 chaperone, 7B2, is expressed only in liver CRC 
metastases
Since PC2 processing is controlled by its specific binding
protein 7B2, we quantified 7B2 expression profiles in nor-
mal and unaffected livers compared to liver metastasis.
RT-PCR amplification of 7B2 led to an expected 454 bp
product and showed a ~3-fold (P < 0.003) increase of 7B2
mRNA in metastasis compared to unaffected or normal
liver (Fig. 3A). By immunoblotting, we were not able to
detect any 7B2 in both unaffected and normal liver, while
an intense immunoreactive band was observed at the
expected 7B2 molecular mass of 21 kDa [8]) in metastasis
samples (Fig. 3C).
Immunohistochemical validation
Using the antibodies described above, we characterized
PC1, PC2 and 7B2 localization by immunohistochemis-
try. PC1 staining was cytoplasmic and more abundant in
areas of tumor than in adjacent unaffected liver, where
only a few cells were positively stained (Fig. 4B, 4C), thus
correlating with the mRNA and immunoblot data. PC2
was present in areas of tumor, and adjacent unaffected
parenchyma (Fig. 5B, 5C). In addition, 7B2 was detected
by very strong cytoplasmic staining in areas of liver metas-
tasis while adjacent unaffected liver did not stain (Fig. 6B,
6C). Finally, although normal liver stained for PC1 (Fig.
4A) and PC2 (Fig. 5A), 7B2 remained undetectable (Fig.
6A).
Immunohistochemistry for PC1 in normal and unaffected liver compared to colorectal (CRC) liver metastasesFigure 4
Immunohistochemistry for PC1 in normal and unaf-
fected liver compared to colorectal (CRC) liver 
metastases. A. Light microscopy immunohistochemistry of 
normal liver (N), using 100 × magnification. Arrowheads indi-
cate the scarcely positively stained hepatic cells. B. Light 
microscopy PC1 immunohistochemistry of liver metastasis 
(T) and adjacent unaffected parenchyma (U), using 20 × mag-
nification. Arrowheads indicate positively stained tumor cells. 
C. Light microscopy PC1 immunohistochemistry of liver 
metastasis (T) using 400 × magnification. Arrowheads indi-
cate positively stained tumor cells.Page 6 of 11
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observed in metastases is only found in a subset of primary 
colon cancers
Using the antibodies described above, we assessed the
presence as well as the processing profile of PC1 and PC2
in primary colon cancers using immunoblot. PC1 was
detected in various amounts in primary colon cancers but
was undetectable in their unaffected counterparts (Fig.
7A). Immunoblot analysis revealed two immunoreactive
species of 84 and 66 kDa, respectively. The higher molec-
ular mass isoform (84 kDa) corresponded to the full-
length active PC1 whereas the C-terminally immunoreac-
tive 66 kDa isoform was likely to be an N-terminally trun-
cated, inactive form of PC1. The ratio of the two isoforms
varied among specimens with 3 out of 5 specimens
expressing more abundant the 84 kDa isoform. PC2 was
also detected in various amounts in primary colon cancers
and was undetectable in their unaffected counterparts
(Fig. 7B). Furthermore, the active 66 kD isoform was more
abundant in 2 out of 5 specimens. In these specific speci-
mens (2 out of five), immunoblot analysis revealed an
intense immunoreactive band at the expected 7B2 molec-
ular mass of 21 kDa (Fig. 7C). These results demonstrate
a strong heterogeneity in the expression/processing of
PC1, PC2 and 7B2 in primary colon cancers compared to
liver metastases, As a consequence they suggest that the
expression/processing pattern of these convertases
observed in liver metastases may represent an important
feature of these cancers.
Discussion
In this study, we assessed the presence and the cleavage/
processing patterns of the two major convertases of the
regulated secretory pathway, PC1 and PC2, as well as the
PC2 chaperone 7B2. This study was performed in human
liver metastases specimens from colorectal primaries and
in unaffected liver samples from the same patients that
underwent liver resection, as well as in normal livers. We
also assessed these convertase profiles in primary colon
cancers.
To our knowledge this is the first report describing the
expression of PC1, PC2 and 7B2 in human liver tissues,
and in human colon cancers. More importantly, we noted
that (i) at the mRNA level, PC1 is overexpressed in meta-
static tumor versus unaffected and normal liver, while
PC2 expression is downregulated (Fig. 1A and 2A respec-
tively); (ii) consistently, at the protein level, PC1
(p84+p66) is overexpressed (Fig. 1D), while PC2
(p75+p66) is downregulated in metastatic tumor (Fig.
2D); (iii) both active PC1 and PC2 are predominant in
metastatic tumor (Fig. 1D and 2D respectively); (iv) con-
sistently with the enhanced PC2 zymogen processing pat-
tern, in tumor, 7B2 is overexpressed (Fig. 3A and 3C); (v)
Immunohistochemistry for PC2 in normal and unaffected liver compared to colorectal (CRC) liver metastasesFigure 5
Immunohistochemistry for PC2 in normal and unaf-
fected liver compared to colorectal (CRC) liver 
metastases. A. Light microscopy PC2 immunohistochemis-
try of normal liver (N), using 400 × magnification. Arrow-
heads indicate positively stained hepatic cells. B. Light 
microscopy PC2 immunohistochemistry of liver metastasis 
(T) and adjacent unaffected parenchyma (U), using 25 × mag-
nification. Arrowheads indicate positively stained cells mainly 
in the unaffected liver. C. Light microscopy PC2 immunohis-
tochemistry of liver metastasis (T) using 200 × magnification. 
Arrowheads indicate positively stained tumor cells.Page 7 of 11
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istry (Fig. 4, 5, 6).
We also found that the specific PC2 and 7B2 profile
observed in metastatic cancers was observed only in a frac-
tion of primary colon cancers. These data support a spe-
cific negative feedback mechanism regulating PC2 mRNA
expression in liver metastases, when PC2 proteolytic activ-
ity is overwhelming. Therefore in metastatic tumors,
abundant active PC2 may lead to a downregulation of its
mRNA, and vice versa in unaffected and normal liver. Fur-
thermore, the homogeneous liver metastasis PC2 protein
profile supports the hypothesis of a tightly regulated
active PC2 production in the primary as well as in meta-
static tumors, with 7B2 playing a leading role in this
mechanism. Interestingly, PC1, PC2 and 7B2 are consid-
ered as markers of endocrine and neuroendocrine pheno-
types [5,8,12]. The fact that they are also detected in
human anal canal [13] from which also cancers and even-
tually metastases can develop suggests that a neuroendo-
crine differentiation program could take place during
colon carcinogenesis and liver metastasis. Recently, a spe-
cific RE1-lk silencer element in the promoter of PC2 was
identified [17] and binding of transcription-silencing fac-
tors to this element may contribute to repression of the
PC2 gene in non-neuroendocrine cells.
Our results are in agreement with recent experimental ani-
mal evidence highlighting the potential implication of
convertases in tumorigenesis and metastasis. Indeed,
Khatib et al. have shown that convertase inhibition in the
HT-29 colon cancer cell line is followed by decreased
invasiveness and tumorigenicity [14]. In addition it has
been shown that furin, another member of the convertase
family, is implicated in tumor progression in human head
and neck malignancies [15]. Convertase overexpression
can also alter the growth behavior and the drug respon-
siveness in a human breast cancer cell line model [16]. In
the past, 7B2 has been implicated with several types of
neuroendocrine tumors, such as neuroendocrine bron-
chial tumors, nonfunctioning pancreatic islet tumors and
ACTH-secreting pituitary tumors [17,18], mainly partici-
pating at the processing of tumor-secreted active peptides.
However its role in tumorigenesis and metastasis, espe-
cially in colorectal cancer, remains largely unknown.
Other groups have also recently showed the implication
of several members of the convertase family in the car-
cinogenesis process. Specifically Siegfried et al have clearly
shown that members of the convertase family process
VEGF-C, a known tumorigenic growth factor, in animal
models [19]. The same group has demonstrated that con-
vertases are involved in the processing of pro-platelet
derived growth factor A, a hallmark of carcinogenesis [20],
Immunohistochemistry for 7B2 in normal and unaffected liver co pared  colorectal (CRC) liver metastasesFigure 6
Immunohistochemistry for 7B2 in normal and unaf-
fected liver compared to colorectal (CRC) liver 
metastases. A. Light microscopy 7B2 immunohistochemis-
try of normal liver (N), using 400 × magnification. No posi-
tive cells were identified. B. Light microscopy 7B2 
immunohistochemistry of liver metastasis (T) and adjacent 
unaffected parenchyma (U), using 100 × magnification. 
Arrowheads indicate positively stained cells uniquely in the 
metastasis. C. Light microscopy 7B2 immunohistochemistry 
of liver metastasis (T) using 400 × magnification. Arrowheads 
indicate dense positively stained tumor cells.Page 8 of 11
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eventually in the treatment of neoplasia.
Our data support the accumulation of active PC1 and PC2
in metastasis, and are in agreement with previous reports
[3,16]. The main question although remains whether
alterations of PC1, PC2 and 7B2 expression profiles are
the cause or consequence of the metastatic phenotype.
PC1 and PC2 process pro-neurotensin to its active form,
which has been involved in colonic tumorigenesis
[21,22], or pro-pancreatic peptide, proGHRH, progluca-
gon, prosomatostatin, and pro-insulin to insulin [23,24],
which are known trophic factors for the gut and possibly
involved in tumorigenesis as well. Indeed, recently it was
Expression of PC1, PC2 and 7B2 in primary colon cancer and unaffected colonFigure 7
Expression of PC1, PC2 and 7B2 in primary colon cancer and unaffected colon. A. PC1 immunoblots in primary 
colon cancer in unaffected colon and in an additional primary colon cancer, note the different PC1 processing pattern between 
the two colon cancers. Experiments were repeated three times. B. Schematic representation of PC1 structure. C. PC2 immu-
noblots in primary colon cancer in unaffected colon and in an additional primary colon cancer. Note the absence of the 66 Kda 
band in the second primary colon cancer. Experiments were repeated three times. D. Schematic representation of PC2 struc-
ture. E. 7B2 immunoblots in primary colon cancer in unaffected colon and in an additional primary colon cancer, indicating 
presence of 7B2 protein only in one tumor. Experiments were repeated three times. Corresponding gels stained with 
Coomassie blue G250 (CS) are shown. F. Schematic representation of 7B2 structure.Page 9 of 11
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PC1 in the processing of GHRH and subsequent growth
[23]. Therefore change in PC1 and PC2 expression and
activation may alter the profiles of secretory proteins,
which in turn could increase cell growth potential. These
changes could lead to selection of primary colon cancer
cells destined to metastasize to the liver or even render the
rest of the liver susceptible to future/further metastasis.
Indeed, the fact that the PC2 profile observed in unaf-
fected liver is partially different from the one observed in
normal liver, supports the hypothesis that the tumor may
induce modifications in the rest of the liver. Whether PC1,
PC2 and 7B2 are directly implicated in such a model is
under investigation, and it would be interesting also to
evaluate the profile of these convertases in different also
metastatic sites such as in the lung or in the brain.
In conclusion, the present study shows that PC1 and PC2
convertase expression and cleavage are altered in CRC
liver metastases. 7B2, whose overexpression in tumor is
thought to play a key role in the above processes, could
represent a potential diagnostic, prognostic or even thera-
peutic target.
Furthermore, the metastasis/tumor associated convertase
profile is observed only in a fraction of primary colon can-
cers thus suggesting a potential selection process for
tumors that eventually will develop metastasis and may
be associated with worse clinical outcome. These observa-
tions require prospective validation that is underway.
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